The future of GLP1 medications: what happens next?

It is easy, in the middle of any technological wave, to assume the present shape of the wave is the shape it will keep. The history of medicine is full of examples to the contrary. The first SSRIs, the first statins, the first immunotherapies — each looked, in their initial years, like the finished product, and each was substantially reshaped over the decade that followed. GLP1 medications are early in their wave. The current versions — Wegovy, Ozempic, Mounjaro, Zepbound — are, almost certainly, not the versions that will define the era ten years from now.

This piece is a clear, plain-English walk through where the GLP1 era appears to be heading — what is in late-stage development, what the next-generation molecules are likely to do differently, how the conversation around access and insurance is shifting, and the slower cultural normalisation that will, in the long run, matter more than any individual drug.

Oral GLP1: the end of the weekly injection

The first major shift on the immediate horizon is the move from injectable to oral GLP1 medications. Novo Nordisk's oral semaglutide (Rybelsus) already exists for type 2 diabetes, and higher-dose oral semaglutide formulations specifically for obesity are in late-stage development. Several other companies, including Eli Lilly with its oral candidate orforglipron, are advancing oral GLP1-class molecules through large clinical trials.

The practical consequences of a genuinely effective once-daily GLP1 pill would be substantial. Manufacturing of pills is dramatically simpler and cheaper than manufacturing of injectable pens, which would ease the supply pressure that has defined the early GLP1 era. The aversion to injections, which keeps a meaningful fraction of potential patients away from the current options, would largely disappear. Distribution to lower-income settings, where injectable cold chains are challenging, would become much more feasible.

The trade-offs are real. Oral GLP1 medications, in their current form, have stricter rules around timing and food intake than injectables do. Effect sizes in some early candidates are slightly less pronounced than what injectables achieve. None of this is a deal-breaker. It does mean the pill version of the era will be a different version of the era — more accessible, slightly less powerful per dose, much more amenable to integration with ordinary primary care.

The next generation: dual, triple, and beyond

If the current frontier is semaglutide (a pure GLP1 agonist) and tirzepatide (a GIP/GLP1 dual agonist), the next frontier is a wave of molecules that hit additional incretin receptors at once. The most-watched candidate is retatrutide, an Eli Lilly compound that activates three receptors — GLP1, GIP, and glucagon — and which, in early trials, has produced weight-loss results notably above what tirzepatide achieves at equivalent durations.

Other companies are advancing alternative combinations — GLP1/amylin agonists like cagrilintide combinations, GLP1/glucagon combinations, and longer-acting once-monthly injectable formulations. Several smaller biotechs are exploring oral non-peptide GLP1 agonists that could be even simpler to manufacture and distribute than the current peptide-based pills.

The realistic outcome of this wave is not a single 'best' molecule, but a family of options matched to different patient profiles — some optimised for maximal weight loss, some for cardiovascular protection, some for metabolic effects beyond weight, some for tolerability. The era is moving from a few headline drugs toward a more differentiated pharmacology, in the same way that the SSRI era eventually produced a family of antidepressants with different profiles.

Beyond weight: the broader disease story

One of the most underappreciated shifts of the next decade will be the slow rewriting of what GLP1 medications are for. Already, semaglutide has shown meaningful cardiovascular benefit in patients with established disease (the SELECT trial), kidney protection in patients with chronic kidney disease, and emerging signals in conditions ranging from heart failure with preserved ejection fraction to non-alcoholic steatohepatitis (now called MASH).

The early data on GLP1 medications in Alzheimer's disease, Parkinson's disease, and various addictive disorders is preliminary but real enough that multiple large trials are now underway. The honest summary is that nobody knows yet how broad the GLP1 family's clinical applications will turn out to be. The cautious summary is that the medications are looking less like 'weight-loss drugs' and more like a class of metabolic-and-neurometabolic agents whose obesity effect is one of several.

If even a fraction of these adjacent indications pan out, the regulatory and cultural framing of the class will shift accordingly. The medications will increasingly be discussed in the same breath as statins — chronic-condition treatments with broad downstream protective effects — rather than as cosmetic or lifestyle tools. That shift has been steadily underway in the medical literature for two years. The public conversation is slower.

The insurance question

The single biggest unresolved question for the next phase of the GLP1 era is access. In the United States in particular, coverage for GLP1 medications for obesity (as opposed to diabetes) remains patchy, expensive, and dependent on individual insurer policies. In much of the world, the medications remain out of reach for most of the patients who would benefit.

Several pressures are pushing this toward broader coverage over the next five years. The accumulating long-term outcome data — fewer heart attacks, fewer strokes, fewer cases of cardiovascular and kidney complications — strengthens the economic argument for coverage. The arrival of pills, with their lower manufacturing costs, will exert downward pressure on prices. The expiration of patents on the first generation of compounds, which begins later in the decade for several agents, will accelerate this further. And competition between Novo Nordisk and Eli Lilly, with new entrants on the way, is already producing pricing dynamics that did not exist when semaglutide was effectively unrivalled.

Whether this produces the kind of broad, affordable access that has characterised statins and antihypertensives over time, or remains a more stratified market, is one of the defining policy questions of the coming decade. The current trend lines suggest broader access, but at a pace slower than patient advocates would like.

Long-term use and what we still don't know

GLP1 medications in their current modern form have only been used at scale for obesity for a few years. The post-marketing data, including the substantial datasets from the cardiovascular outcomes trials, is reassuring. But the field is still in the early years of understanding what a decade or two of continuous use looks like.

The most likely picture, based on what is now known, is that long-term use is largely safe for most patients, that maintaining the weight-loss benefit requires continued use in most cases, and that the cardiovascular and metabolic benefits accumulate over time rather than wash out. Areas worth genuine ongoing study include long-term effects on bone density and lean mass, very long-term effects on certain cancers (the early signals are reassuring but the data is still maturing), and what optimal protocols look like for people who want to step down or off the medication after sustained loss.

None of these uncertainties are reasons to avoid the medications. They are reasons to use them with the same long-term mindset that the field uses for any chronic-condition treatment — paying attention, adjusting as needed, and treating the journey as a multi-year relationship with the medication rather than a one-time event.

AI, tracking, and the GLP1 journal era

A lower shift is the emergence of dedicated digital journals for the GLP1 era. The current generation of generic fitness and tracking apps was built for a different problem — calorie counting, step goals, gym workouts. The patterns that actually matter on GLP1 medications are different: weekly weight trends rather than daily numbers, protein intake on a suppressed appetite, hydration on slowed gastric emptying, energy and sleep through dose changes, the slow emotional recalibration of the journey.

The next several years will see this category mature significantly, with AI-supported tools that can read the patterns in a person's data and surface what is actually changing — what the noisy daily numbers cannot show. The promise is not that AI will replace clinical care; it is that the texture of the long, slow GLP1 journey will be more visible to the person living it, and to the clinicians supporting them, than the current generic tooling allows.

The slower cultural shift

The faster shifts of the next decade — pills, new molecules, broader indications, insurance changes — will get the headlines. The slower shift, which will matter more, is cultural. The GLP1 era has already done substantial work toward normalising obesity as a chronic medical condition rather than a personal failing, and toward normalising medication for it as a legitimate, long-term treatment.

Five years from now, the cultural baseline will have moved further in this direction. The conversation about taking a GLP1 medication for weight management will, for many patients and many clinicians, be closer to the conversation about taking a statin for cholesterol than it is today. The stigma will not disappear entirely. But it will have softened in the way that the stigma around antidepressants softened over the two decades after the first SSRIs arrived.

Alongside that softening will come a more honest cultural reckoning with the things the medications cannot solve. Loneliness, identity, meaning, the long human work of being a person in a body — none of these are GLP1 problems, and none of them will be GLP1 solutions. The mature version of the conversation, which is already emerging, treats the medications as tools that handle the metabolic and appetite problem well enough that the rest of life can finally be addressed on its own terms. That, more than any specific molecule, is the long arc of where the era is heading.

The bigger picture

Step back even further, and the GLP1 era is probably the leading edge of a broader shift in how chronic metabolic conditions are treated. The same logic — long-term medication for a chronic condition, integrated with lifestyle support, normalised culturally — is likely to apply to a wider range of conditions as the underlying biology becomes better understood. The molecules will change. The framing will not.

In that sense, the question of 'what comes next' for GLP1 medications is partly a question of what is next for chronic-condition medicine more broadly. The honest answer is that the next ten years will look, in retrospect, like the early years of a much longer transformation. The current versions of the drugs, the current debates about access, the current cultural choreography — all of these will look, from 2035, like the beginning rather than the middle of the story.

What seems clear, even from inside the early years, is that the GLP1 era will not be remembered as a brief weight-loss fashion. It is more likely to be remembered as the moment the medical world finally got a workable tool for a chronic condition it had been losing to for fifty years — and as the beginning of a longer normalisation of what serious, modern, compassionate metabolic medicine actually looks like.

Follow your own journey through the GLP1 era with GLP1 Journal →